- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01177579
Human Biomarkers for Assessing Copper Deficiency
Human Biomarkers for Assessing Copper Deficiency and Repletion: A Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Nana Gletsu Miller, PhD
- Phone Number: 765-496-9462
- Email: ngletsum@purdue.edu
Study Locations
-
-
Indiana
-
West Lafayette, Indiana, United States, 47906
- Recruiting
- Purdue University
-
Contact:
- Nana Gletsu Miller, PhD
- Phone Number: 765-496-9462
- Email: ngletsum@purdue.edu
-
Principal Investigator:
- Nana Gletsu Miller, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
CuD subjects In order to be enrolled into the CuD Arm, subjects who have had RYGB surgery will be recruited and screened for eligibility (inclusion and exclusion criteria below). Subjects whose plasma copper concentrations are in the deficient range (less than 80 μg/dL for women and less than 70 µg/dL for men, and/or ceruloplasmin activity below 62 units/L-1) following 4 weeks of supplementation with the RDA for copper will be eligible. Such supplementation is the routine standard of care with all patients undergoing RYGB surgery. This process aims to exclude patients who were only marginally copper deficient and not in need of sustained copper therapy. Subjects will be notified about their copper status by a study physician. They will be contacted by the study team, and their willingness to participate in the study will be determined.
Inclusion criteria: 1) Patient has a history of RYGB weight loss surgery; 2) subject has a plasma copper level which is less than 80 μg/dL for women andl less than 70 µg/dL for men, and/or ceruloplasmin activity below 62 units/L-1; 3) subject is at least 18 but not more than 65 years of age; and 4) subject has signed an informed consent.
Exclusion criteria: 1) subject exhibits severe neurologic signs or symptoms (e.g. severe paresthesias, severe gait disturbances, or severe weakness which require intravenous copper supplementation; 2) subject is pregnant; 3) subject has history of surgical revision or conversion of bariatric procedure; 4) subject has a history of hospitalization for acute illness in the previous 3 months; 5) subject has current active malignant neoplasm; or history of malignancy other than localized basal cell cancer of skin during previous 5 years; 6) subject has current history of type 1 or type 2 diabetes mellitus.
CuN subjects In order to be enrolled into the CuN control arm, subjects who have had RYGB surgery will be recruited and screened for eligibility (inclusion and exclusion criteria below). Subjects will have plasma copper concentrations in the normal range (80 - 155 μg/dL for women and 70 - 140 µg/dL for men, and/or ceruloplasmin activity above 62 units/L-1). Subjects will also be eligible if they can be matched for stage of weight management (either active weight loss or weight stable) and gender with a CuD subject. Subjects will be notified about their copper status and their eligibility and their willingness to participate in the study will be determined.
Inclusion criteria: 1) Patient has a history of RYGB weight loss surgery; 2) subject has a plasma copper level which is 80 - 155 μg/dL for women and 70 - 140 µg/dL for men, and/or ceruloplasmin activity above 62 units/L-1; 3) subject can be matched for stage of weight management and gender with a CuD subject, 4) subject is at least 18 but not more than 65 years of age; and 5) subject has signed an informed consent.
Exclusion criteria: 1) subject is pregnant; 2) subject has history of surgical revision or conversion of bariatric procedure; 3) subject has a history of hospitalization for acute illness in the previous 3 months; 4) subject has current active malignant neoplasm; or history of malignancy other than localized basal cell cancer of skin during previous 5 years; 5) subject has current history type 1 or type 2 diabetes mellitus.
NW Control Arm For the normal-weight control arm (NW Control), subjects who have not had bariatric surgery and are of normal weight will be recruited.
Inclusion criteria: 1) Subject has a plasma copper level which is 80 - 155 μg/dL for women and 70 - 140 µg/dL for men, and/or ceruloplasmin activity above 62 units/L-1; 2) subject is of normal weight, BMI between 20 - 30 kg/m2, 3) subject is at least 18 but not more than 65 years of age; and 4) subject has signed an informed consent.
Exclusion criteria: 1) subject is pregnant; 2) subject has history of abdominal surgery or history of gastrointestinal disease; 3) subject has a history of hospitalization for acute illness in the previous 3 months; 4) subject has current active malignant neoplasm; or history of malignancy other than localized basal cell cancer of skin during previous 5 years; 5) subject has current history type 1 or type 2 diabetes mellitus.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Aim 1; Biomarkers
Blood concentrations of copper coenzymes will be monitored for 1 year
|
|
Experimental: Copper supplement Arm
4 mg or 8 mg copper will be compared in a randomized controlled study
|
4 or 8 mg copper gluconate/day will be assessed for efficacy of copper repletion
|
No Intervention: Normal Controls
Normal subjects will be used to generate reference measures.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
copper co-enzymes
Time Frame: 1 year
|
expression of CCS, SOD and COX4 in blood samples
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
blood copper concentrations
Time Frame: 2 months
|
2 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00006969
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Copper Deficiency
-
University of PennsylvaniaCompletedPostpartum | Intrauterine Devices, CopperUnited States
-
EgymedicalpediaCompletedCopper Intrauterine Device Induced BleedingEgypt
-
University of UtahCompletedMenstruation | Metrorrhagia | Menstrual Cycle | Intrauterine Devices, CopperUnited States
-
Cyprium Therapeutics, Inc.Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedMenkes Disease | Occipital Horn Syndrome | Unexplained Copper DeficiencyUnited States
-
Shi YunRecruitingAging | Diminished Ovarian Reserve | Biomarker | Premature Ovarian Insufficiency | Copper | CeruloplasminChina
-
Nutrition Institute, SloveniaEuropean Regional Development Fund; Vizera d.o.o.; Frutarom Etol d.o.o.CompletedVitamin B 12 Deficiency | Vitamin d Deficiency | Protein DeficiencySlovenia
-
Washington University School of MedicineUniversity of California, Davis; Universidad San Francisco de Quito; Pan American...CompletedCholine Deficiency | Vitamin B-12 Deficiency | Lipids Deficiency | Amino Acids DeficiencyEcuador
-
Texas A&M UniversityUnknownCognitive Change | Nutritional Anemia | Diet, Healthy | Nutrient Deficiency | Diet; Deficiency | Visual Spatial Processing | Dietary Deficiency | Dietary B12 Deficiency | Dietary Zinc Deficiency | Dietary Vitamin B12 Deficiency Anemia | Dietary Deficiency of Selenium and Vitamin EUnited States
-
SourseCitruslabsActive, not recruitingMood | Energy Supply; Deficiency | B12 Deficiency VitaminUnited States
-
University of California, DavisUniversity of California, San Francisco; University of Rhode Island; Ethiopian... and other collaboratorsNot yet recruitingVitamin B 12 Deficiency | Folate Deficiency | Iodine Deficiency | Anemia Deficiency | Salt Intake | Anemia Macrocytic
Clinical Trials on Copper gluconate
-
University of UtahCompleted
-
Daniel George, MDCantex Pharmaceuticals; The V Foundation for Cancer Research; Give 1 For Dad... and other collaboratorsTerminatedProstate CancerUnited States
-
HonorHealth Research InstituteCantex PharmaceuticalsTerminatedMetastatic Pancreatic CancerUnited States
-
University of UtahCantex PharmaceuticalsTerminatedMultiple MyelomaUnited States
-
Albert Einstein College of MedicineCompletedIntrauterine Device ExpulsionUnited States
-
University of Sao Paulo General HospitalEdson Santos Ferreira-Filho; Nilson Roberto de Melo; Isabel Cristina Esposito... and other collaboratorsRecruiting
-
Washington University School of MedicineCompletedGlioblastomaUnited States
-
Aurora Health CareTerminatedGlioblastoma | Glioblastoma MultiformeUnited States
-
Universidad del DesarrolloCompletedHealthcare Associated InfectionChile